Literature DB >> 84263

Chlorpromazine reduces fluid-loss in cholera.

G H Rabbani, W B Greenough, J Holmgren, I Lönnroth.   

Abstract

Because chlorpromazine inhibited cholera-toxin-stimulated intestinal adenylate cyclase and fluid secretion in laboratory animals its ability to reduce fluid-loss in human cholera was investigated. Eleven cholera patients with severe purging (360--1340 ml/h) were studied. Eight were given chlorpromazine intramuscularly (1 mg/kg of 4 mg/kg), and three were given a dose of 1 mg/kg by mouth. In the 32 hours after treatment there was an overall reduction in stool output of 66 +/- 5% in the chlorpromazine-treated patients. This decrease was significantly larger than the 26 +/- 9% reduction in stool output seen in patients not receiving the drug, who were observed at the same time in the course of their illness. The decrease in nausea and the mild sedation produced by chlorpromazine added to the patients' comfort. No hypotension was seen in these well-hydrated patients.

Entities:  

Keywords:  Biology; Clinical Research; Diarrhea; Diseases; Fluid Balance; Homeostasis; Physiology; Research Methodology

Mesh:

Substances:

Year:  1979        PMID: 84263     DOI: 10.1016/s0140-6736(79)90885-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

Review 1.  Pharmacoeconomics of the therapy of diarrhoeal disease.

Authors:  K A Nathavitharana; I W Booth
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

2.  Failure of chlorpromazine to inhibit fluid accumulation caused by Escherichia coli heat-stable enterotoxin in suckling mice.

Authors:  T Takeda; T Honda; Y Takeda; T Miwatani
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

3.  Acute secretory diarrheas. Current concepts in pathogenesis and treatment.

Authors:  S Hughes
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

4.  Lanthanum chloride inhibition of the secretory response to Escherichia coli heat-stable enterotoxin.

Authors:  R N Greenberg; F Murad; R L Guerrant
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

Review 5.  Antidiarrheal therapy. Prospects for new agents.

Authors:  R N Fedorak; M Field
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

6.  Calcium mediation of the pig jejunal secretory response.

Authors:  G W Forsyth; P H Wong; D D Maenz
Journal:  Can J Comp Med       Date:  1985-04

7.  Differentiation of secretagogue drugs by chlorpromazine in rat intestine in vivo.

Authors:  U M Farack; G Nell; W Rummel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

8.  Effect of chlorpromazine on the secretory activity of Escherichia coli heat-stable enterotoxin.

Authors:  D M Abbey; F C Knoop
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

9.  Jejunal water and electrolyte secretion induced by L-arginine in man.

Authors:  J E Hegarty; P D Fairclough; M L Clark; A M Dawson
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

10.  Inhibition of Escherichia coli heat-stable enterotoxin by indomethacin and chlorpromazine.

Authors:  R N Greenberg; F Murad; B Chang; D C Robertson; R L Guerrant
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.